178 related articles for article (PubMed ID: 37998349)
1. Single-Cell Analysis Differentiates the Effects of p53 Mutation and p53 Loss on Cell Compositions of Oncogenic Kras-Driven Pancreatic Cancer.
Sun X; Yang D; Chen Y
Cells; 2023 Nov; 12(22):. PubMed ID: 37998349
[TBL] [Abstract][Full Text] [Related]
2. Cell of origin affects tumour development and phenotype in pancreatic ductal adenocarcinoma.
Lee AYL; Dubois CL; Sarai K; Zarei S; Schaeffer DF; Sander M; Kopp JL
Gut; 2019 Mar; 68(3):487-498. PubMed ID: 29363536
[TBL] [Abstract][Full Text] [Related]
3. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer.
Morton JP; Timpson P; Karim SA; Ridgway RA; Athineos D; Doyle B; Jamieson NB; Oien KA; Lowy AM; Brunton VG; Frame MC; Evans TR; Sansom OJ
Proc Natl Acad Sci U S A; 2010 Jan; 107(1):246-51. PubMed ID: 20018721
[TBL] [Abstract][Full Text] [Related]
4. SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice.
Ogawa S; Fukuda A; Matsumoto Y; Hanyu Y; Sono M; Fukunaga Y; Masuda T; Araki O; Nagao M; Yoshikawa T; Goto N; Hiramatsu Y; Tsuda M; Maruno T; Nakanishi Y; Hussein MS; Tsuruyama T; Takaori K; Uemoto S; Seno H
Gastroenterology; 2020 Aug; 159(2):682-696.e13. PubMed ID: 32360551
[TBL] [Abstract][Full Text] [Related]
5. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
6. A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.
Keenan BP; Saenger Y; Kafrouni MI; Leubner A; Lauer P; Maitra A; Rucki AA; Gunderson AJ; Coussens LM; Brockstedt DG; Dubensky TW; Hassan R; Armstrong TD; Jaffee EM
Gastroenterology; 2014 Jun; 146(7):1784-94.e6. PubMed ID: 24607504
[TBL] [Abstract][Full Text] [Related]
7. Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma.
Lakshmanan I; Marimuthu S; Chaudhary S; Seshacharyulu P; Rachagani S; Muniyan S; Chirravuri-Venkata R; Atri P; Rauth S; Nimmakayala RK; Siddiqui JA; Gautam SK; Shah A; Natarajan G; Parte S; Bhyravbhatla N; Mallya K; Haridas D; Talmon GA; Smith LM; Kumar S; Ganti AK; Jain M; Ponnusamy MP; Batra SK
Oncogene; 2022 Nov; 41(48):5147-5159. PubMed ID: 36271032
[TBL] [Abstract][Full Text] [Related]
8. Zeb1 in Stromal Myofibroblasts Promotes
Sangrador I; Molero X; Campbell F; Franch-Expósito S; Rovira-Rigau M; Samper E; Domínguez-Fraile M; Fillat C; Castells A; Vaquero EC
Cancer Res; 2018 May; 78(10):2624-2637. PubMed ID: 29490942
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet.
Luo Y; Yang Y; Liu M; Wang D; Wang F; Bi Y; Ji J; Li S; Liu Y; Chen R; Huang H; Wang X; Swidnicka-Siergiejko AK; Janowitz T; Beyaz S; Wang G; Xu S; Bialkowska AB; Luo CK; Pin CL; Liang G; Lu X; Wu M; Shroyer KR; Wolff RA; Plunkett W; Ji B; Li Z; Li E; Li X; Yang VW; Logsdon CD; Abbruzzese JL; Lu W
Gastroenterology; 2019 Nov; 157(5):1413-1428.e11. PubMed ID: 31352001
[TBL] [Abstract][Full Text] [Related]
10. Loss of Rnf43 Accelerates Kras-Mediated Neoplasia and Remodels the Tumor Immune Microenvironment in Pancreatic Adenocarcinoma.
Hosein AN; Dangol G; Okumura T; Roszik J; Rajapakshe K; Siemann M; Zaid M; Ghosh B; Monberg M; Guerrero PA; Singhi A; Haymaker CL; Clevers H; Abou-Elkacem L; Woermann SM; Maitra A
Gastroenterology; 2022 Apr; 162(4):1303-1318.e18. PubMed ID: 34973294
[TBL] [Abstract][Full Text] [Related]
11. Loss of HIF1A From Pancreatic Cancer Cells Increases Expression of PPP1R1B and Degradation of p53 to Promote Invasion and Metastasis.
Tiwari A; Tashiro K; Dixit A; Soni A; Vogel K; Hall B; Shafqat I; Slaughter J; Param N; Le A; Saunders E; Paithane U; Garcia G; Campos AR; Zettervall J; Carlson M; Starr TK; Marahrens Y; Deshpande AJ; Commisso C; Provenzano PP; Bagchi A
Gastroenterology; 2020 Nov; 159(5):1882-1897.e5. PubMed ID: 32768595
[TBL] [Abstract][Full Text] [Related]
12. p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation-driven pancreatic cancer.
Miller P; Akama-Garren EH; Owen RP; Demetriou C; Carroll TM; Slee E; Al Moussawi K; Ellis M; Goldin R; O'Neill E; Lu X
Cell Death Differ; 2023 Jul; 30(7):1619-1635. PubMed ID: 37270580
[TBL] [Abstract][Full Text] [Related]
13. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
[TBL] [Abstract][Full Text] [Related]
14. Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden.
Salehi-Rad R; Li R; Tran LM; Lim RJ; Abascal J; Momcilovic M; Park SJ; Ong SL; Shabihkhani M; Huang ZL; Paul M; Shackelford DB; Krysan K; Liu B; Dubinett SM
Cancer Immunol Immunother; 2021 Aug; 70(8):2389-2400. PubMed ID: 33507343
[TBL] [Abstract][Full Text] [Related]
15. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
16. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma.
Zhang W; Nandakumar N; Shi Y; Manzano M; Smith A; Graham G; Gupta S; Vietsch EE; Laughlin SZ; Wadhwa M; Chetram M; Joshi M; Wang F; Kallakury B; Toretsky J; Wellstein A; Yi C
Sci Signal; 2014 May; 7(324):ra42. PubMed ID: 24803537
[TBL] [Abstract][Full Text] [Related]
17. A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers.
Cheng R; Li F; Zhang M; Xia X; Wu J; Gao X; Zhou H; Zhang Z; Huang N; Yang X; Zhang Y; Shen S; Kang T; Liu Z; Xiao F; Yao H; Xu J; Yan C; Zhang N
Cell Res; 2023 Jan; 33(1):30-45. PubMed ID: 36241718
[TBL] [Abstract][Full Text] [Related]
18. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.
Viale A; Pettazzoni P; Lyssiotis CA; Ying H; Sánchez N; Marchesini M; Carugo A; Green T; Seth S; Giuliani V; Kost-Alimova M; Muller F; Colla S; Nezi L; Genovese G; Deem AK; Kapoor A; Yao W; Brunetto E; Kang Y; Yuan M; Asara JM; Wang YA; Heffernan TP; Kimmelman AC; Wang H; Fleming JB; Cantley LC; DePinho RA; Draetta GF
Nature; 2014 Oct; 514(7524):628-32. PubMed ID: 25119024
[TBL] [Abstract][Full Text] [Related]
19. p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells.
Bailey JM; Hendley AM; Lafaro KJ; Pruski MA; Jones NC; Alsina J; Younes M; Maitra A; McAllister F; Iacobuzio-Donahue CA; Leach SD
Oncogene; 2016 Aug; 35(32):4282-8. PubMed ID: 26592447
[TBL] [Abstract][Full Text] [Related]
20. Activation Of Wild-Type Hras Suppresses The Earliest Stages Of Pancreatic Cancer.
Weyandt J
Redox Biol; 2015 Aug; 5():414. PubMed ID: 28162272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]